294 related articles for article (PubMed ID: 30712287)
1. Short- and long-term responsiveness to low dose growth hormone (GH) in adult GH deficiency: Role of GH receptor polymorphism.
Bianchi A; Giampietro A; Tartaglione L; Chiloiro S; Gentilella R; Bima C; Anile C; Olivi A; Pontecorvi A; De Marinis L
J Neuroendocrinol; 2019 Apr; 31(4):e12692. PubMed ID: 30712287
[TBL] [Abstract][Full Text] [Related]
2. The d3-growth hormone (GH) receptor polymorphism is associated with increased responsiveness to GH in Turner syndrome and short small-for-gestational-age children.
Binder G; Baur F; Schweizer R; Ranke MB
J Clin Endocrinol Metab; 2006 Feb; 91(2):659-64. PubMed ID: 16291706
[TBL] [Abstract][Full Text] [Related]
3. Growth hormone receptor isoforms and fracture risk in adult-onset growth hormone-deficient patients.
Mormando M; Chiloiro S; Bianchi A; Giampietro A; Angelini F; Tartaglione L; Nasto L; Milardi D; Formenti AM; Giustina A; De Marinis L
Clin Endocrinol (Oxf); 2016 Nov; 85(5):717-724. PubMed ID: 27437620
[TBL] [Abstract][Full Text] [Related]
4. Influence of the d3-growth hormone (GH) receptor isoform on short-term and long-term treatment response to GH replacement in GH-deficient adults.
van der Klaauw AA; van der Straaten T; Baak-Pablo R; Biermasz NR; Guchelaar HJ; Pereira AM; Smit JW; Romijn JA
J Clin Endocrinol Metab; 2008 Jul; 93(7):2828-34. PubMed ID: 18397980
[TBL] [Abstract][Full Text] [Related]
5. Influence of the d3GH receptor polymorphism on the metabolic and biochemical phenotype of GH-deficient adults at baseline and during short- and long-term recombinant human GH replacement therapy.
Giavoli C; Ferrante E; Profka E; Olgiati L; Bergamaschi S; Ronchi CL; Verrua E; Filopanti M; Passeri E; Montefusco L; Lania AG; Corbetta S; Arosio M; Ambrosi B; Spada A; Beck-Peccoz P
Eur J Endocrinol; 2010 Sep; 163(3):361-8. PubMed ID: 20592127
[TBL] [Abstract][Full Text] [Related]
6. Impact of the exon 3-deleted growth hormone (GH) receptor polymorphism on baseline height and the growth response to recombinant human GH therapy in GH-deficient (GHD) and non-GHD children with short stature: a systematic review and meta-analysis.
Wassenaar MJ; Dekkers OM; Pereira AM; Wit JM; Smit JW; Biermasz NR; Romijn JA
J Clin Endocrinol Metab; 2009 Oct; 94(10):3721-30. PubMed ID: 19584188
[TBL] [Abstract][Full Text] [Related]
7. The d3/fl-GH receptor gene polymorphism does not influence quality of life and body composition in GH-deficient adults receiving GH replacement therapy.
Adetunji OR; MacFarlane IA; Javadpour M; Alfirevic A; Pirmohamed M; Blair JC
Eur J Endocrinol; 2009 Oct; 161(4):541-6. PubMed ID: 19605543
[TBL] [Abstract][Full Text] [Related]
8. Influence of growth hormone receptor d3 and full-length isoforms on biochemical treatment outcomes in acromegaly.
Bianchi A; Giustina A; Cimino V; Pola R; Angelini F; Pontecorvi A; De Marinis L
J Clin Endocrinol Metab; 2009 Jun; 94(6):2015-22. PubMed ID: 19336510
[TBL] [Abstract][Full Text] [Related]
9. d3-GHR genotype does not explain heterogeneity in GH responsiveness in hypopituitary adults.
Moyes VJ; Walker DM; Owusu-Antwi S; Maher KT; Metherell L; Akker SA; Monson JP; Clark AJ; Drake WM
Clin Endocrinol (Oxf); 2010 Jun; 72(6):807-13. PubMed ID: 20039885
[TBL] [Abstract][Full Text] [Related]
10. The exon 3-deleted/full-length growth hormone receptor polymorphism and response to growth hormone therapy in growth hormone deficiency and Turner syndrome: a multicenter study.
Baş F; Darendeliler F; Aycan Z; Çetinkaya E; Berberoğlu M; Sıklar Z; Öcal G; Timirci Ö; Çetinkaya S; Darcan Ş; Gökşen Şimşek D; Bideci A; Cinaz P; Böber E; Demir K; Bereket A; Turan S; Atabek ME; Tütüncüler F; Isbir T; Bozkurt N; Kabataş Eryılmaz S; Uzunhan O; Küçükemre Aydın B; Bundak R
Horm Res Paediatr; 2012; 77(2):85-93. PubMed ID: 22456308
[TBL] [Abstract][Full Text] [Related]
11. Association of the exon 3 deleted/full-length GHR polymorphism with recombinant growth hormone dose in growth hormone-deficient adults.
Meyer S; Schaefer S; Stolk L; Arp P; Uitterlinden AG; Plöckinger U; Stalla GK; Tuschy U; Weber MM; Weise A; Pfützner A; Kann PH
Pharmacogenomics; 2009 Oct; 10(10):1599-608. PubMed ID: 19842933
[TBL] [Abstract][Full Text] [Related]
12. Influence of the exon 3 deletion of GH receptor and IGF-I level at diagnosis on the efficacy and safety of treatment with somatotropin in adults with GH deficiency.
Andujar-Plata P; Fernandez-Rodriguez E; Quinteiro C; Casanueva FF; Bernabeu I
Pituitary; 2015 Feb; 18(1):101-7. PubMed ID: 24710993
[TBL] [Abstract][Full Text] [Related]
13. Influence of the exon 3-deleted/full-length growth hormone (GH) receptor polymorphism on the response to GH replacement therapy in adults with severe GH deficiency.
Barbosa EJ; Palming J; Glad CA; Filipsson H; Koranyi J; Bengtsson BA; Carlsson LM; Boguszewski CL; Johannsson G
J Clin Endocrinol Metab; 2009 Feb; 94(2):639-44. PubMed ID: 19050057
[TBL] [Abstract][Full Text] [Related]
14. Additive effect of GHRd3 and COLIA1 polymorphisms on the GH-substitution dose in GH-deficient adults.
Hartleb S; Plöckinger U; Stalla GK; Tuschy U; Weber MM; Pfützner A; Kann PH; ;
Pharmacogenomics; 2011 Dec; 12(12):1653-61. PubMed ID: 22026923
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of the peripheral sensitivity to growth hormone in adults with GH deficiency.
Aimaretti G; Fanciulli G; Bellone S; Maccario M; Arvat E; Delitala G; Camanni F; Ghigo E
Eur J Endocrinol; 2001 Sep; 145(3):267-72. PubMed ID: 11517006
[TBL] [Abstract][Full Text] [Related]
16. Correlation between exon 3 polymorphism of growth hormone receptor gene and the responses to rhGH therapy.
Wei Y; Zheng R; Zhou Y; Wang J; Bao P
Int J Clin Exp Pathol; 2015; 8(6):7371-7. PubMed ID: 26261638
[TBL] [Abstract][Full Text] [Related]
17. Growth hormone (GH) dose, but not exon 3-deleted/full-length GH receptor polymorphism genotypes, influences growth response to two-year GH Therapy in Short Small-for-Gestational-Age Children.
Carrascosa A; Audí L; Esteban C; Fernández-Cancio M; Andaluz P; Gussinyé M; Clemente M; Yeste D; Albisu MA
J Clin Endocrinol Metab; 2008 Jan; 93(1):147-53. PubMed ID: 17925340
[TBL] [Abstract][Full Text] [Related]
18. MECHANISMS IN ENDOCRINOLOGY: Clinical and pharmacogenetic aspects of the growth hormone receptor polymorphism.
Boguszewski CL; Barbosa EJL; Svensson PA; Johannsson G; Glad CAM
Eur J Endocrinol; 2017 Dec; 177(6):R309-R321. PubMed ID: 28904008
[TBL] [Abstract][Full Text] [Related]
19. SNPs within the GH-signaling pathway are associated with the early IGF1 response to GH replacement therapy in GHD adults.
Glad CA; Barbosa EJ; Filipsson Nyström H; Carlsson LM; Nilsson S; Nilsson AG; Svensson PA; Johannsson G
Eur J Endocrinol; 2014 Jan; 170(1):101-7. PubMed ID: 24114431
[TBL] [Abstract][Full Text] [Related]
20. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF GROWTH HORMONE DEFICIENCY IN ADULTS AND PATIENTS TRANSITIONING FROM PEDIATRIC TO ADULT CARE.
Yuen KCJ; Biller BMK; Radovick S; Carmichael JD; Jasim S; Pantalone KM; Hoffman AR
Endocr Pract; 2019 Nov; 25(11):1191-1232. PubMed ID: 31760824
[No Abstract] [Full Text] [Related]
[Next] [New Search]
